http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101760277-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-05 |
filingDate | 2010-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2017-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2017-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-101760277-B1 |
titleOfInvention | T-cell receptor |
abstract | The present invention relates to a method of binding a peptide from latent membrane protein 2 (LMP-2) of Epstein Barr virus (EBV) having the amino acid sequence CLGGLLTMV (SEQ ID NO: 1) when presented by a primary histocompatibility complex (MHC) T-cell receptor (TCR). The present invention also provides nucleotide sequences encoding TCR, vectors containing nucleotide sequences, and uses thereof to generate EBV-specific T cells. The invention also provides the use of EBV-specific T-cells for cellular immunotherapy. |
priorityDate | 2009-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 700.